Search

Your search keyword '"Fahy, M"' showing total 12 results
Start Over Author "Fahy, M" Journal circulation
12 results on '"Fahy, M"'

1. Prevalence, distribution, predictors, and outcomes of patients with calcified nodules in native coronary arteries: a 3-vessel intravascular ultrasound analysis from Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT).

Author

Xu Y, Mintz GS, Tam A, McPherson JA, Iñiguez A, Fajadet J, Fahy M, Weisz G, De Bruyne B, Serruys PW, Stone GW, Maehara A, Xu, Yingjia, Mintz, Gary S, Tam, Anthony, McPherson, John A, Iñiguez, Andrés, Fajadet, Jean, Fahy, Martin, and Weisz, Giora

Published
2012
Full Text
View/download PDF

2. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.

Author

Rosner GF, Kirtane AJ, Genereux P, Lansky AJ, Cristea E, Gersh BJ, Weisz G, Parise H, Fahy M, Mehran R, Stone GW, Rosner, Gregg F, Kirtane, Ajay J, Genereux, Philippe, Lansky, Alexandra J, Cristea, Ecaterina, Gersh, Bernard J, Weisz, Giora, Parise, Helen, and Fahy, Martin

Published
2012
Full Text
View/download PDF

4. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy.

Author

Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Stone GW, Goto, Kenji, Lansky, Alexandra J, Fahy, Martin, Cristea, Ecatarina, Feit, Frederick, Ohman, E Magnus, and White, Harvey D

Published
2010
Full Text
View/download PDF

5. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial.

Author

Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW, Pocock, Stuart J, Mehran, Roxana, Clayton, Tim C, Nikolsky, Eugenia, Parise, Helen, Fahy, Martin, and Lansky, Alexandra J

Published
2010
Full Text
View/download PDF

9. Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions

Author

Tullio Palmerini, Giora Weisz, Martin Fahy, LeRoy E. Rabbani, Bruce R. Brodie, Giulio Guagliumi, Helen Parise, Adriano Caixeta, D Dudek, Roxana Mehran, Bernhard Witzenbichler, Ke Xu, George Dangas, Philippe Généreux, Eugenia Nikolsky, Alexandra J. Lansky, Gregg W. Stone, Palmerini T., Mehran R., Dangas G., Nikolsky E., Witzenbichler B., Guagliumi G., Dudek D., Genereux P., Caixeta A., Rabbani L., Weisz G., Parise H., Fahy M., Xu K., Brodie B., Lansky A., and Stone G.W.

Subjects
Male, leukocyte count, medicine.medical_specialty, Percutaneous, medicine.medical_treatment, Hemorrhage, Revascularization, Predictive Value of Tests, Risk Factors, Physiology (medical), Angioplasty, Internal medicine, medicine, Humans, Myocardial infarction, Angioplasty, Balloon, Coronary, ANGIOPLASTY, Creatine Kinase, Aged, business.industry, MYOCARDIAL INFARCTION, Hazard ratio, angioplasty, Stent, Percutaneous coronary intervention, Middle Aged, STENTS, medicine.disease, Confidence interval, myocardial infarction, stents, Cardiology, Female, Cardiology and Cardiovascular Medicine, business
Abstract

Background— The relationship between white blood cell count (WBCc) and mortality in patients with ST-segment–elevation acute myocardial infarction treated with percutaneous coronary intervention is poorly understood. Furthermore, whether there is a relationship between WBCc and risk of noncardiac mortality and bleeding after percutaneous coronary intervention is unknown. Methods and Results— The baseline WBCc was available in 3193 of 3345 patients (95.5%) who underwent percutaneous coronary intervention in the Harmonizing Outcome With Revascularization and Stent in Acute Myocardial Infarction (HORIZONS-AMI) trial. In a propensity-adjusted multivariable analysis, WBCc was an independent predictor of 1-year cardiac mortality (hazard ratio, 1.15; 95% confidence interval, 1.09 to 1.22), noncardiac mortality (hazard ratio, 1.19; 95% confidence interval, 1.10 to 1.29), and major bleeding (hazard ratio, 1.08; 95% confidence interval, 1.04 to 1.12). After adjustment for baseline creatinine phosphokinase levels and left ventricular ejection fraction, WBCc remained an independent predictor of 1-year all-cause mortality and cardiac mortality. In patients matched for baseline creatinine phosphokinase levels at hospital admission, the median peak creatinine phosphokinase level was significantly higher in patients with high WBCc (>11 000 per 1 mm 3 ) compared with low WBCc (1851 U/L [range, 880-3307 U/L] versus 1241 U/L [range, 540 to 2,78], respectively; P Conclusions— In patients with ST-segment–elevation acute myocardial infarction undergoing percutaneous coronary intervention, elevated baseline WBCc is an independent predictor of infarct size, as assessed by peak creatinine phosphokinase level, and of 1-year cardiac mortality, noncardiac mortality, and major bleeding. Clinical Trial Registration— URL: http://www.ClinicalTrials.gov . Unique identifier: NCT00433966.

Published
2011
Full Text
View/download PDF

10. Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial.

Author

Kario K, Böhm M, Mahfoud F, Townsend RR, Weber MA, Patel M, Tyson CC, Weil J, Agdirlioglu T, Cohen SA, Fahy M, and Kandzari DE

Subjects
Humans, Hypertension diagnosis, Hypertension physiopathology, Predictive Value of Tests, Time Factors, Treatment Outcome, Autonomic Denervation methods, Blood Pressure, Blood Pressure Monitoring, Ambulatory, Circadian Rhythm, Hypertension surgery, Kidney innervation
Published
2018
Full Text
View/download PDF

11. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.

Author

Stone GW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, and Smits PC

Subjects
Everolimus, Humans, Immunosuppressive Agents therapeutic use, Randomized Controlled Trials as Topic statistics & numerical data, Sirolimus therapeutic use, Tubulin Modulators therapeutic use, Angioplasty, Balloon, Coronary methods, Coronary Artery Disease therapy, Diabetic Angiopathies therapy, Drug-Eluting Stents, Paclitaxel therapeutic use, Sirolimus analogs & derivatives
Abstract

Background: Some (but not all) prior trials have reported differential outcomes after percutaneous coronary intervention with paclitaxel-eluting stents versus stents eluting rapamycin analogs according to the presence of diabetes mellitus. These studies lacked sufficient power to examine individual safety and efficacy end points., Methods and Results: To determine whether an interaction exists between the presence of diabetes mellitus and treatment with everolimus-eluting stents compared with paclitaxel-eluting stents, we pooled the databases from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) II, SPIRIT III, SPIRIT IV, and A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice (COMPARE) trials in which percutaneous coronary intervention was performed in 6780 patients, 1869 (27.6%) of whom had diabetes mellitus. Patients without diabetes mellitus treated with everolimus-eluting stents compared with paclitaxel-eluting stents had significantly reduced 2-year rates of mortality (1.9% versus 3.1%; P=0.01), myocardial infarction (2.5% versus 5.8%; P<0.0001), stent thrombosis (0.3% versus 2.4%; P<0.0001), and ischemia-driven target lesion revascularization (3.6% versus 6.9%; P<0.0001). In contrast, among patients with diabetes mellitus, there were no significant differences between the 2 stent types in any measured safety or efficacy parameter. Significant interactions were present between diabetic status and stent type for the 2-year end points of myocardial infarction (P=0.01), stent thrombosis (P=0.0006), and target lesion revascularization (P=0.02)., Conclusions: We have identified a substantial interaction between diabetes mellitus and stent type on clinical outcomes after percutaneous coronary intervention. In patients without diabetes mellitus, everolimus-eluting stents compared with paclitaxel-eluting stents resulted in substantial 2-year reductions in death, myocardial infarction, stent thrombosis, and target lesion revascularization, whereas no significant differences in safety or efficacy outcomes were present in diabetic patients.

Published
2011
Full Text
View/download PDF

12. Response to letters regarding article, “Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy”.

Author

Lansky A, Goto K, Fahy M, Cristea E, Mehran R, Stone GW, Feit F, Ohman EM, Alexander KP, White HD, Bertrand ME, Desmet W, and Hamon M

Subjects
Female, Humans, Male, Acute Coronary Syndrome drug therapy, Anticoagulants therapeutic use, Coronary Angiography, Heparin therapeutic use, Peptide Fragments therapeutic use, Platelet Aggregation Inhibitors therapeutic use
Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results